Seres Therapeutics, Inc.
Seres Therapeutics, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing live biotherapeutic product candidates. Its pipeline includes SER-155, SER-603, and SER-147, and its operations are centered on microbiome-based therapies and related manufacturing capabilities in Cambridge, Massachusetts.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaPipeline LBP programs being developed for infectious, inflammatory, and immune-related diseases.
Human-data-driven discovery capabilities used to identify and advance new LBP candidates.
Internal cGMP manufacturing and related support for drug substance and drug product.
Asiakkaat
Seres does not currently sell approved products broadly; its economic relationships are primarily with collaborators, development partners, and contract counterparties that support research, manufacturing, and transition services. If its pipeline advances, its eventual customers would include hospitals, physicians, and payors involved in treatment decisions for medically vulnerable patient populations.
They support development, transition services, and other contractual arrangements tied to pipeline programs.
CROs, CMOs, and testing labs that buy or provide development and manufacturing support.
Potential future users of approved therapies such as SER-155 in transplant settings.
Prescribers who would recommend any approved product in medically vulnerable populations.
Insurers and government programs that would determine coverage and reimbursement.
Strategia
Seres is focused on advancing SER-155 and its other wholly owned live biotherapeutic candidates through clinical development and regulatory review. It is also preserving manufacturing capability, intellectual property, and collaboration flexibility so it can support future commercialization if a candidate is approved.
SER-155 is the lead remaining program and the main near-term value driver.
Live biotherapeutics require specialized cGMP production and supply control.
Patent and know-how protection are central to differentiation in microbiome therapeutics.
Any approved product would require sales, distribution, and reimbursement infrastructure.
Maantiede
Seres is headquartered and manufactures in the United States, with cGMP operations in Cambridge, Massachusetts. Its business is primarily U.S.-based today, while its intellectual property, collaboration rights, and future commercialization potential may extend to other markets.
Riskit
Seres faces the typical risks of a clinical-stage biotech company: clinical failure, regulatory delay, and the need for additional capital before product sales are established. Its concentration in a smaller number of live biotherapeutic programs also increases exposure to scientific, manufacturing, and competitive setbacks.
- Need for additional capitalVaikutus: KriittinenTodennäköisyys: Korkea
Development and commercialization require funding before product revenue exists.
Kohdistuu: Advancing SER-155 and other pipeline programs
- Clinical development failureVaikutus: KorkeaTodennäköisyys: Korkea
Pipeline value depends on positive trial outcomes and acceptable safety.
Kohdistuu: SER-155 and other LBP candidates
- Regulatory approval delay or denialVaikutus: KorkeaTodennäköisyys: Korkea
LBPs must clear FDA review and may face evolving regulatory expectations.
Kohdistuu: All product candidates
- Manufacturing and supply complexityVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Live biotherapeutics require controlled cultivation, testing, and cGMP processes.
Kohdistuu: Cambridge manufacturing and third-party CMOs
- Competition from larger biopharma companiesVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Competitors may have more resources and faster development timelines.
Kohdistuu: Microbiome and inflammatory disease programs
Kirjanpito
Harkinnanvaraiset erätRevenue has been derived primarily from collaborator agreements, so timing depends on contract milestones and services delivered.
Vaikutus: Can create uneven quarterly revenue recognition
The VOWST business was sold and its results are presented separately from continuing operations.
Vaikutus: Affects trend analysis and segment comparability
Clinical and manufacturing services often arrive before invoices, requiring estimates.
Vaikutus: Can shift reported R&D expense between periods
Derivative or warrant instruments may be remeasured through earnings.
Vaikutus: Can add non-operating volatility to reported results
A meaningful non-cash expense for a development-stage biotech.
Vaikutus: Impacts operating loss and expense comparability
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Cero Therapeutics Holdings, Inc.
CEROW · Biological Products, (No Diagnostic Substances)
Terns Pharmaceuticals, Inc.
Pharmaceutical Preparations
Serina Therapeutics, Inc.
SER · Pharmaceutical Preparations
Marker Therapeutics, Inc.
MRKR · Pharmaceutical Preparations
SELLAS Life Sciences Group, Inc.
SLS · Pharmaceutical Preparations
SELLAS Life Sciences Group is a U.S.-based late-stage clinical biopharmaceutical company focused on developing cancer therapeutics.
Keros Therapeutics, Inc.
KROS · Pharmaceutical Preparations
Keros Therapeutics is a clinical-stage biopharmaceutical company developing protein therapeutics for disorders driven by dysfunctional TGF-β family signaling.
Päivitetty: 24.9.2026